Biomarker Data Repository

C-Path is developing a repository for data on novel translational safety biomarkers from drug development programs, with the goal of accelerating qualification of novel biomarkers as new tools for drug developers. This initial pilot focuses on kidney safety biomarkers.

CURE Drug Repurposing Collaboratory

CDRC is designed to capture real-world clinical outcome data to advance drug repurposing and inform future clinical trials for diseases of high unmet medical need.

Critical Path for Sickle Cell Disease

CP-SCD aims to accelerate drug development for sickle cell disease through collaborative development and regulatory endorsement of new medical product development tools. CP-SCD will work with the sickle cell community to identify and prioritize tools needed to optimize drug development, such as outcome assessments and disease progression models.

Critical Path For Alzheimer's Disease

The Critical Path For Alzheimer’s Disease (CPAD) is a public-private partnership aimed at creating new tools and methods that can be applied to increase the efficiency of the development process of new treatments for Alzheimer disease (AD) and related neurodegenerative disorders with impaired cognition and function.

Critical Path for Parkinson's

Created in partnership with Parkinson’s UK, one of the world’s largest charity funders of Parkinson’s research, the Critical Path for Parkinson’s Consortium (CPP) was launched on October 14, 2015.

Critical Path to Therapeutics for the Ataxias

CPTA is a public-private partnership with the mission                                                                                    to optimize clinical trials for inherited ataxias.

Critical Path to TB Drug Regimens

The CPTR initiative is dedicated to delivering a safer, more efficacious, and faster-acting tuberculosis (TB) regimen by developing and promoting innovative regulatory science essential for supporting new combination drug development in collaboration with its partners across industry, academia, and government.

Duchenne Regulatory Science Consortium

D-RSC supports collaborative research through shared data access and development of drug development tools.

Data Collaboration Center

Developing data solutions for scientific research.

Electronic Clinical Outcome Assessment Consortium

The Electronic Clinical Outcome Assessment (eCOA) Consortium provides scientific leadership and best practice recommendations surrounding electronic data capture technologies and services that support the collection of patient-focused outcomes data in clinical trials.

Huntington’s Disease Regulatory Science Consortium

Created in partnership with CHDI Foundation and the Critical Path Institute, HD-RSC was launched on March 28, 2018, with the aim of accelerating the regulatory approval of Huntington’s disease therapies.

International Neonatal Consortium

Launched on May 19, 2015, INC is C-Path’s ninth consortium – a global collaboration formed to forge a predictable regulatory path for evaluating the safety and effectiveness of therapies for neonates.

Multiple Sclerosis Outcome Assessments Consortium

Launched in December, 2012, MSOAC is another dynamic partnership formed to promote consensus science. Created jointly with the National Multiple Sclerosis Society,  MSOAC will collect, standardize, and analyze data about MS with the goal of qualifying a new measure of disability as a primary or secondary endpoint for future trials of MS therapies.

Polycystic Kidney Disease Outcomes Consortium

C-Path's Polycystic Kidney Disease (PKD) Outcomes Consortium is a collaborative partnership whose research leads to discovery of treatments for PKD.

PredicTox Knowledge Environment

The aim of the PredicTox Knowledge Environment (KE) project is to advance the science of adverse event prediction by creating an integrated web-based knowledge environment consisting of multiple interconnected databases that capture quantitative multiscale biology of drug action.

Patient-Reported Outcome Consortium

The Patient-Reported Outcome Consortium supports patient-focused drug development by obtaining qualification of clinical outcome assessment tools that measure how patients feel and function in their everyday lives as a result of treatment.

Predictive Safety Testing Consortium

C-Path's Predictive Safety Testing Consortium (PSTC) serves as a neutral third party in the independent assessment and validation of drug safety tests.

Quantitative Medicine Program

C-Path’s Quantitative Medicine program aims to improve population and individual health by transforming drug development through methodological innovation.

Rare Disease Clinical Outcome Assessment Consortium

The Rare Disease Clinical Outcome Assessment Consortium enables precompetitive, multi-stakeholder collaboration aimed at identifying scientifically sound tools and methodologies for collecting clinically meaningful outcomes data in treatment trials for rare diseases.

Rare Disease Cures Accelerator-Data and Analytics Platform

RDCA-DAP is an FDA-funded initiative that will provide a centralized and standardized infrastructure to support and accelerate rare disease characterization with the goal of accelerating therapy development.

System of Hospitals for Innovation in Pediatrics – Medical Devices

The National Innovation Ecosystem for Pediatric Medical Devices

Type 1 Diabetes Consortium

The T1D Consortium is working to qualify islet autoimmunity antibodies as prognostic biomarkers to be used in the development of therapies for the treatment, and ultimately the prevention, of type 1 diabetes.

TB-Platform for Aggregation of Clinical TB Studies

The TB-PACTS data platform is designed to catalyze and accelerate TB research by curating and standardizing Phase III tuberculosis (TB) clinical trial data and making this data publicly available to qualified researchers.

Trial Outcome Markers Initiative in T1D

TOMI-T1D’s mission is to accelerate drug development in T1D with the goal of slowing or preventing disease progression. By aggregating patient-level data from previously conducted clinical trials, TOMI-T1D will develop and seek the regulatory endorsement of a clinical trial simulation tool capable of de-risking decision making and optimizing the design of clinical trials.

Translational Therapeutics Accelerator

The Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) is a novel drug discovery and development program focused on supporting academic scientists in advancing cutting-edge new therapeutics from the lab to commercialization and patient care.

Transplant Therapeutics Consortium

Co-founded by the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS), the Transplant Therapeutics Consortium (TTC) is a collaboration between the transplant community, industry, and regulatory agencies, and is managed and supported by Critical Path Institute (C-Path).